PT-141 (Bremelanotide)
Works through your nervous system to boost sexual desire and arousal -- it acts on the brain, not the blood vessels (unlike Viagra). It's actually FDA-approved under the name Vyleesi for low sex drive in women.
What to Expect
Week 1–2
Effects are acute — sexual arousal and desire increase within 1-4 hours of dosing. Not used continuously. Nausea is common on first use.
Week 3–6
Continued as-needed use. Effects remain consistent with each dose. Side effects typically diminish with experience. Optimal dosing established.
Week 8+
Sustained efficacy with as-needed dosing. No cumulative benefits — mechanism is acute CNS activation per dose.
Common Side Effects
Scientific Overview
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It selectively activates melanocortin-4 receptors (MC4R) in the central nervous system, specifically in the medial preoptic area and paraventricular nucleus, to initiate sexual arousal through dopaminergic pathway activation. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts on the central nervous system rather than peripheral vasculature.
Dosing
1.75 mg subq about 45 minutes before you need it. Don't use more than once in 24 hours, and it's not meant for daily use.
Practical Guide
Reconstitution
Pre-filled autoinjector (Vyleesi) or reconstitute 10mg vial with 2mL BAC water. Typical dose 1.75mg.
Storage
Refrigerate reconstituted solution. Use within 30 days. Autoinjectors stored at room temperature.
Injection Sites
Subcutaneous injection. Use as needed — not a daily medication. Max 1 dose per 24 hours, 8 per month.
Timing
Inject 45-60 minutes before anticipated sexual activity. Effects last 6-12 hours. First dose often causes most nausea.
Food
Avoid heavy meals before dosing — nausea is common. Light meal 2 hours prior is fine.
Benefit Profile
Medical Considerations
Contraindications
- ✕Uncontrolled hypertension
- ✕Cardiovascular disease
- ✕Pregnancy/nursing
- ✕Concurrent use with other melanocortin agonists
Drug Interactions
Recommended Monitoring
- →Blood pressure before and after dosing
- →Monitor for skin/mole changes
- →Heart rate monitoring
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Safety Profile of Bremelanotide Across the Clinical Development Program.
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Novel Pharmacologic Treatments of Female Sexual Dysfunction.
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.